Matthew J Wakefield
Overview
Explore the profile of Matthew J Wakefield including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
5900
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nesic K, Rybinski K, Ratnayake G, Ho G, Lim R, Radke M, et al.
Clin Transl Med
. 2025 Mar;
15(3):e70274.
PMID: 40074693
No abstract available.
2.
Rubin A, Stone J, Bianchi A, Capodanno B, Da E, Dias M, et al.
Genome Biol
. 2025 Jan;
26(1):13.
PMID: 39838450
Multiplexed assays of variant effect (MAVEs) are a critical tool for researchers and clinicians to understand genetic variants. Here we describe the 2024 update to MaveDB ( https://www.mavedb.org/ ) with...
3.
Nesic K, Krais J, Wang Y, Vandenberg C, Patel P, Cai K, et al.
Mol Cancer
. 2024 Aug;
23(1):158.
PMID: 39103848
PARP inhibitor (PARPi) therapy has transformed outcomes for patients with homologous recombination DNA repair (HRR) deficient ovarian cancers, for example those with BRCA1 or BRCA2 gene defects. Unfortunately, PARPi resistance...
4.
Xu L, Liddell B, Nesic K, Geissler F, Ashwood L, Wakefield M, et al.
NAR Cancer
. 2024 Jul;
6(3):zcae033.
PMID: 39055334
In ovarian and breast cancer, promoter methylation of or is a promising biomarker for PARP inhibitor response, as high levels lead to homologous recombination deficiency (HRD). Yet the extent and...
5.
Xu H, Gitto S, Ho G, Medvedev S, Shield-Artin K, Kim H, et al.
iScience
. 2024 Jul;
27(7):109978.
PMID: 39021796
High-grade serous ovarian cancers (HGSOCs) with homologous recombination deficiency (HRD) are initially responsive to poly (ADP-ribose) polymerase inhibitors (PARPi), but resistance ultimately emerges. HGSOC with amplification ( ) are associated...
6.
Gu K, Mok L, Wakefield M, Chong M
Sci Rep
. 2024 Mar;
14(1):6713.
PMID: 38509178
The RNase III enzyme Drosha has a central role in microRNA (miRNA) biogenesis, where it is required to release the stem-loop intermediate from primary (pri)-miRNA transcripts. However, it can also...
7.
Geissler F, Nesic K, Kondrashova O, Dobrovic A, Swisher E, Scott C, et al.
Ther Adv Med Oncol
. 2024 Jan;
16:17588359231220511.
PMID: 38293277
Epigenetic alterations, including aberrant DNA methylation, are now recognized as hallmarks of cancer, which can contribute to cancer initiation, progression, therapy responses and therapy resistance. Methylation of gene promoters can...
8.
Ho G, Vandenberg C, Lim R, Christie E, Garsed D, Lieschke E, et al.
Ther Adv Med Oncol
. 2023 Nov;
15:17588359231208674.
PMID: 38028140
Background: Despite initial response to platinum-based chemotherapy and PARP inhibitor therapy (PARPi), nearly all recurrent high-grade serous ovarian cancer (HGSC) will acquire lethal drug resistance; indeed, ~15% of individuals have...
9.
Marks Z, Campbell N, Mangan N, Vandenberg C, Gearing L, Matthews A, et al.
Nature
. 2023 Aug;
620(7976):1063-1070.
PMID: 37587335
High-grade serous ovarian cancers have low survival rates because of their late presentation with extensive peritoneal metastases and frequent chemoresistance, and require new treatments guided by novel insights into pathogenesis....
10.
Dall G, Vandenberg C, Nesic K, Ratnayake G, Zhu W, Vissers J, et al.
J Exp Clin Cancer Res
. 2023 May;
42(1):112.
PMID: 37143137
Background: Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA...